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trols during the euthymic and depressive mood state, while 
bipolar II patients showed a trend towards higher sICAM-1 
levels during depression. Patients with bipolar I disorders 
had significantly higher sICAM-1 levels during manic states 
when compared to controls (p = 0.007).  Conclusions: 
sICAM-1 elevation in unipolar and bipolar patients, indepen-
dent of mood changes, might support the hypothesis of 
chronic immune activation and endothelial dysfunction in 
patients with affective disorders.  © 2016 S. Karger AG, Basel 
 Introduction 
 Recent findings suggest that chronic immune stimula-
tion, including higher levels of pro-inflammatory cyto-
kines, acute-phase proteins, chemokines and cellular ad-
hesion molecules, may play a role in the pathophysiology 
of mood changes in unipolar and bipolar disorders  [1, 2] . 
The most consistent findings are elevated interleukin-6 
(IL-6) and tumor necrosis factor alpha (TNF-α) levels in 
patients with unipolar depressive disorders  [3] and an in-
crease in soluble IL-2 receptor (sIL-2R), TNF-α, soluble 
tumor necrosis factor receptor type 1 (sTNFR1), sIL-6R 
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 Abstract 
 Background: Immunological and vascular markers may play 
a role in the pathophysiology of mood disorders and mood 
changes.  Aim: To test whether the cell adhesion molecule 
soluble intracellular adhesion molecule-1 (sICAM-1) may 
serve as a biomarker for patients with unipolar or bipolar af-
fective disorders when compared to a healthy control group, 
and whether sICAM-1 blood levels change during different 
mood states.  Methods: sICAM-1 serum concentrations were 
compared between 20 healthy controls and 48 patients with 
affective disorders (unipolar, bipolar II and bipolar I disorder) 
during different mood states (euthymic mood state, depres-
sion or mania).  Results: When compared to healthy controls, 
patients with affective disorders had significantly higher
sICAM-1 levels during the euthymic state (p = 0.015). Differ-
ences became more pronounced during depression (p = 
0.013). When unipolar and bipolar patients were analyzed 
separately, unipolar patients significantly differed from con-
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and IL-4 in patients with bipolar disorder  [1] . However, 
it remains unclear how peripheral immune activation 
might affect the brain and induce mood changes like
depression or mania if the blood-brain barrier (BBB) is 
intact.
 The intracellular adhesion molecule-1 (ICAM-1) on 
the BBB endothelial cells appears to be a major mediator 
of leukocyte immigration into the central nervous sys-
tem. Soluble ICAM-1 (sICAM-1) is an indirect parame-
ter of increased ICAM-1 expression on activated im-
mune or endothelial cells. In inflammatory neurological 
diseases, elevated levels of soluble ICAM-1 are assumed 
to be an indicator for an impairment of the BBB, with an 
increased invasion of macrophages/microglia or cyto-
kines in the central nervous system  [4–6] . Elevated blood 
levels of the cell adhesion molecule ICAM-1 have been 
shown to be associated with depressive mood states in 
elderly patients, patients with vascular-related depres-
sion, or patients with depression during immune treat-
ment  [7–10] . We recently reported a correlation between 
elevated plasma levels of sICAM-1 and depressive symp-
toms in patients with malignant melanoma who received 
adjuvant therapy with the cytokine interferon-alpha  [9] . 
Elevations in sICAM-1 have further been observed in pa-
tients with chronic stress as a risk factor for both immune 
activation and depressive mood changes  [11] . Finally, 
higher sICAM-1 levels in the cerebrospinal fluid were 
very recently shown to be predictive for depression in 
individuals with traumatic brain injuries  [12] . Taken to-
gether, ICAM-1 might be involved in the pathophysiol-
ogy of vascular- and immune-associated mood changes. 
We therefore investigated in a pilot trial sICAM-1 con-
centrations in patients with unipolar or bipolar affective 
disorders during different mood states (euthymia, de-
pression or mania) and compared them to those of 
healthy controls. Our trial aimed to explore different or 
abnormal adhesion molecule expression (sICAM-1) in 
unipolar and bipolar mood disorders, to compare this to 
healthy controls, and to determine its possible role as a 
biomarker.
 Patients and Methods 
 Patients were eligible for the study if they were between 18 and 
70 years old and had a diagnosis of unipolar depression or bipolar 
disorder according to the diagnostic criteria of DSM-IV and ICD-
10. Exclusion criteria were any other axis I disorders (DSM-IV), 
significant chronically immunological or acute inflammatory dis-
orders, or severe neurological, cardiovascular, hepatic, renal, met-
abolic, or other severe somatic diseases. We also excluded patients 
with clinically relevant abnormalities in laboratory tests and fe-
male subjects who are pregnant or breastfeeding. Participants were 
grouped into different diagnostic categories: patients with unipo-
lar or bipolar affective disorder (bipolar II and bipolar I) using the 
Structured Clinical Interview for DSM-IV axis I disorders (SCID). 
Data from patients with affective disorders was compared with 
those of a control group matched for age and gender without any 
history of psychiatric disorders. Controls were also free of somatic 
disorders, acute infections or chronic immune disorders and did 
not receive medication. The study was approved by the local ethics 
review board. All patients gave their informed consent.
 Clinical Ratings 
 A diagnosis of acute depressive or manic episodes was made by 
an experienced psychiatrist according to the DSM-IV criteria. The 
severity of depression or mania was evaluated with the Hamilton 
Depression Scale (HAMD, 17-item version) and with the Young 
Mania Rating Scale (YMRS). Patients were not included during 
hypomanic episodes. Euthymic patients did not show manic or 
depressive symptoms and had to have been stable for the last 4 
weeks. All patients were monitored over a period of 12 months, 
and if possible, blood was taken during different mood states. If 
patients were included during a euthymic state, they were followed 
for up to 12 months in our outpatient clinic and seen every 4 weeks 
to detect possible relevant depressive or manic episodes. When-
ever possible, patients who were included during a period of de-
pression or mania were followed after treatment to collect data 
during stabilized euthymic episodes.
 Measurements 
 sICAM-1 was measured during different mood states (euthy-
mic mood state or acute depression). Overall, we compared 20 
controls with 48 patients who had affective disorders: 11 patients 
with unipolar depression, 13 patients with bipolar II disorder (BP-
II) and 24 patients with bipolar I disorder (BP-I). For the evalua-
tion of sICAM-1, blood was taken between 9: 00 and 12: 00 a.m. 
Serum levels of sICAM-1 were measured by a commercially avail-
able double-sandwich ELISA (CELLFREE human sICAM-1, En-
dogen, Rockford, Ill., USA). The detection limit was 0.3 ng/ml.
The mean values for intra- and inter-assay variability were found 
to be <7.5%. Laboratory personnel were unaware of the patient’s 
diagnosis or clinical status. All measurements were done in dupli-
cates. The paired samples of one patient were measured within one 
assay. All assays of the immune parameters were carried out with 
a single lot number of reagents and consumables employed by a 
single operator.
 Statistical Evaluation 
 For the systematic evaluation of sICAM-1, a stepwise compar-
ison of patients and healthy controls was performed with indepen-
dent t tests. The stepwise data analysis was also used because of the 
pilot character of the trial and the relatively low number of patients 
in the subgroups. In the first step, sICAM-1 levels were compared 
between patients and controls in general. In the second step, we 
used univariate analysis of variance (ANOVA) to compare
sICAM-1 levels between patients with unipolar affective disorders, 
bipolar affective disorders and controls. In the third step, we were 
interested in detecting the differences between patients in the BP-I 
and BP-II subgroups, unipolar patients and controls. Linear re-
gression analysis was used to analyze the influence of possible con-




















   
   
   
   
   
   
   
   
   
   
   


























mood stabilizers, antipsychotics or combination therapy) con-
cerning sICAM-1 levels in unipolar and bipolar patients during 
euthymic, depressive or manic mood states. Finally, we compared 
sICAM-1 levels between different mood states independent of di-
agnosis by t tests (for two groups) or ANOVA (for more than two 
groups). For baseline analysis, we compared continuous variables 
with independent t tests and categorical variables with χ 2 tests. The 
association between depression and mania ratings scores on the 
one hand and sICAM-1 serum levels on the other was analyzed by 
using Pearson’s correlation. Bonferroni adjustment was used to 
correct for multiple comparisons.
 Results 
 Overall data of 20 healthy controls was compared with 
those of 48 patients: 11 with unipolar and 37 with bipolar 
affective disorder (24 BP-I and 13 BP-II). The baseline 
data are shown in  table 1 . Significant differences between 
the unipolar, BP-I and BP-II patients during euthymic 
mood states was found for HAMD (F 2, 42 = 4.515, p = 
0.017) and YMRS (F 2, 42 = 5.505, p = 0.008). During eu-
thymic mood states, unipolar patients had significantly 
higher HAMD scores when compared to BP-I patients
(p = 0.038). BP-I patients showed significantly higher 
scores in the YMRS when compared to unipolar (p = 
0.012) or BP-II patients (p = 0.008). Based on the trial’s 
naturalistic design, the type and dosage of medication was 
not restricted. Medication had to have been stable for at 
least 1 week. Most patients were treated with mood stabi-
lizers (lithium, valproate) and/or antidepressants (venla-
faxine, sertraline, paroxetine, amitriptyline) and/or atyp-
ical antipsychotics (olanzapine, risperidone). Only 4 pa-
tients received typical antipsychotics (perazine, 
haloperidol, flupentixol).
 sICAM-1 Concentrations Differ between Euthymic 
Patients and Controls 
 Stable euthymic patients with unipolar or bipolar mood 
disorders had significantly higher sICAM-1 concentra-
tions when compared to healthy controls (t = 2.501, d.f. = 
58, p = 0.015) ( fig. 1 a). A comparison of sICAM-1 levels 
(ANOVA) between unipolar, BP-I and BP-II patients and 
healthy controls confirmed a significant difference be-
tween the subgroup of unipolar patients and healthy con-
trols (p = 0.018, 95% CI 18.5–187.3) ( fig. 1 b). However, 
BP-II patients showed a strong trend towards higher
sICAM-1 levels compared to controls (p = 0.057, 95% CI 
–2.3 to 160.5). sICAM-1 levels did not differ between pa-









Age, years 46.1 ± 13.9 55.8 ± 12.2 49.1 ± 17.8 38.67 ± 15.2
Female 13 (65%) 8 (73%) 11 (85%) 13 (54%)
Medication
No medication 20 (100%) 2 (18%) 0 0
AD 0 5 (45%) 7 (54%) 0
MS 0 0 1 (8%) 9 (38%)
AP 0 1 (9%) 0 1 (4%)
BD 0 0 0 1 (4%)
AD+MS 0 1 (9%) 2 (15%) 2 (8%)
AD+AP 0 1 (9%) 2 (15%) 6 (25%)
MS+AP 0 0 0 3 (13%)
AD+MS+AP 0 1 (9%) 0 2 (8%)
HAMD
Euthymic 8.3 ± 2.9 (n = 10) 7.4 ± 6.9 (n = 12) 3.6 ± 3.9 (n = 23)
Depressive 28.6 ± 5.4 (n = 11) 25.8 ± 7.8 (n = 13) 24.2 ± 15.1 (n = 9)
YMRS
Euthymic 1.4 ± 1.7 (n = 10) 1.4 ± 1.1 (n = 12) 4.3 ± 3.8 (n = 23)
Depressive 2.4 ± 1.3 (n = 11) 2.6 ± 1.5 (n = 13) 3.0 ± 2.5 (n = 9)




















   
   
   
   
   
   
   
   
   
   
   


























tients with unipolar or bipolar disorder. Concentrations 
of sICAM-1 did not correlate with depression scores (r = 
–0.207, p = 0.299), but were positively correlated with age 
(r = 0.345, p = 0.029). According to regression analysis, 
age, gender and medication were not associated with
sICAM-1 levels in unipolar or bipolar patients.
 sICAM-1 Levels Are Increased during Depression and 
Mania when Compared to Healthy Controls 
 During depression, patients with mood disorders 
showed significantly higher sICAM-1 concentrations 
when compared to controls (t = 2.584, d.f. = 51, p = 0.013) 
( fig. 1 a). Regarding the subgroups, sICAM-1 levels were 
significantly higher in unipolar patients when compared 
to controls (p = 0.012, 95% CI 21.2–160.5). BP-II patients 
showed a strong trend towards higher sICAM-1 levels 
compared to controls (p = 0.053, 95% CI –0.87 to 131.3) 
( fig. 1 b). sICAM-1 levels did not differ between unipolar 
and bipolar patients during depression (p = 0.301, 95%
CI –32.64 to 103.43), and sICAM-1 levels were not cor-
related with the severity of depression (HAMD score).
 In patients with BP-I disorder, sICAM-1 concentra-
tions were significantly higher during mania as compared 
to controls (t = 2.871, d.f. = 33, p = 0.007) ( fig.  1 a).
sICAM-1 levels were again not correlated with symptom 
severity (YMRS, r = –0.132, p = 0.639), but positively cor-
related with age (r = 0.524, p = 0.045). Other possible con-
founders such as gender and medication were not sig-
nificantly related to sICAM-1 concentrations in unipolar 
and bipolar patients.
 sICAM-1 Levels Did Not Show Changes in a Subgroup 
of Patients with Remission after Mania or Depression 
 We also looked at intra-individual changes of sICAM-
1 blood levels in the subgroup of patients with unipolar 
and bipolar disorders who could be followed during dif-
ferent mood states (euthymia versus depression or ma-

































BP-II Unipolar Controls Unipolar BP-II
















 Fig. 1.  a Comparison of sICAM-1 levels in 
stable euthymic, depressive or manic pa-
tients with unipolar or bipolar mood disor-
ders and healthy controls (mean ± SD).
 b Comparison of sICAM-1 levels (ANO-
VA) between healthy controls and unipolar,
BP-II and BP-I patients during the euthy-




















   
   
   
   
   
   
   
   
   
   
   


























patients who recovered and reached a euthymic mood 
state when compared to depression (unipolar patients:
F 1, 8 = 0.312, p = 0.592; BP-II patients: F 1, 9 = 0.013, p = 
0.912). In addition, sICAM-1 levels did not differ in re-
mitted BP-I patients with a euthymic mood state com-
pared to blood levels during their manic episode (t = 
0.818, d.f. = 12, p = 0.429) or depression (t = 1.167, d.f. = 
1, p = 0.451).
 Discussion 
 Our findings demonstrate for the first time, indepen-
dent of mood changes, a stable sICAM-1 elevation in pa-
tients with unipolar and bipolar affective disorders when 
compared to a healthy control group. However, when 
subgroups in our trial were compared separately, differ-
ences only became significant for patients with unipolar 
affective disorders, based on the relatively low number of 
patients per group. A further notable observation were 
the mild but continuous differences between unipolar, 
BP-II and BP-I patients, possibly indicating a discrimi-
nating property of sICAM-1 between unipolar and bipo-
lar disorders and supporting the concept of diagnostic 
differentiation between unipolar, BP-II and BP-I patients. 
However, differences between the patient subgroups 
(uni polar, BP-I and BP-II) were not significant and have 
to be reinvestigated with larger collectives. sICAM-1 lev-
els did not differ between patients with acute episodes of 
depression or mania when compared to patients in a sta-
ble euthymic state. This observation may support the hy-
pothesis of a trait marker for patients with unipolar or 
bipolar affective disorders.
 sICAM-1 has been used in clinical trials as a biomark-
er for endothelial activation and dysfunction  [13] . It has 
also been investigated as an important marker in a vascu-
lar disease animal model of depression  [14] . Endothelial 
dysfunction contributes to the pathogenesis, severity and 
progression of a variety of potentially serious infectious 
diseases and syndromes  [15] . In addition, increased
sICAM-1 concentrations have been found before or dur-
ing neuroinflammatory conditions such as tick-borne en-
cephalitis, neuroborreliosis or systemic lupus erythema-
tosus with central nervous system involvement indicating 
disturbances of the BBB  [16, 17] . In this context, our data 
give evidence to an involvement of the vascular system 
and chronic immune activation in the pathophysiology of 
mood disorders. Elevation or pathological expression of 
sICAM-1 might, independent of mood state, represent a 
mechanism for a subclinical BBB dysfunction which en-
ables pro-inflammatory cytokines to enter the brain and 
induce depressive symptoms. Baldwin and O’Brien  [18] 
emphasized a concept of ‘vascular depression’ in which 
changes in the vascular integrity might be involved in 
metabolic changes in the central nervous system, possibly 
followed by neurotransmitter or neurotoxic and struc-
tural changes. Increased expression in the brain of ICAM-
1 and elevated plasma levels of sICAM-1 have been re-
ported in patients with depression after acute coronary 
syndrome and in elderly patients  [8, 10, 19] . Data from 
van Sloten et al.  [19] further supported the view that en-
dothelial dysfunction might be associated with the patho-
biology of depression in elderly people. For patients with 
recent acute coronary syndromes, Lesperance et al.  [8] 
could demonstrate an association between depression 
and elevated sICAM-1 levels even after adjustment for 
potential confounders (gender, smoking, presence of 
metabolic syndrome). sICAM-1 was also shown to pre-
dict depression symptom severity after 12 months in 
heart failure patients  [20] . Our trial with elevations in
sICAM-1 in a group of younger patients with mood dis-
orders might indicate that activation of cellular adhesion 
molecules is not limited to elderly people or patients with 
cardiovascular problems.
 A very recent trial found increased ICAM and vascular 
cell adhesion molecule levels in bipolar patients during 
their first manic episode. The authors also found a weak 
correlation between ICAM levels and the severity of man-
ic symptoms measured by the YMRS  [21] . In contrast to 
our data, cell adhesion molecules decreased during sub-
sequent remission and did not differ when compared to 
healthy controls. However, data are limited to mania, 
while patients with depression were excluded. In addition 
to its possible role as a vascular risk factor during inflam-
matory conditions, sICAM-1 was shown to be increased 
in patients with adiposity, metabolic syndrome, diabetes 
and dyslipidemia, and in smokers as a common risk fac-
tors for vascular disorders  [21–23] . However, in the trial 
by Turan et al.  [21] , the increase in cellular adhesion mol-
ecules was independent of all other cardiovascular risk 
factors besides smoking behavior. People with unipolar 
or bipolar affective disorders are more prone to develop 
diabetes mellitus and vascular disease. On the other hand, 
adiposity and diabetes are associated with an increased 
risk for depressive mood changes, possibly associated 
with chronic low-grade inflammation  [24, 25] . In this 
context, sICAM-1 elevation might be a common patho-
genetic factor for mood disorders and mood changes dur-
ing metabolic disorders, diabetes, chronic low-grade in-




















   
   
   
   
   
   
   
   
   
   
   


























also support the hypothesis of a subclinical increased per-
meability of the BBB  [26] . Future trials may also assess the 
relationships adhesion molecule expression with steroid 
regulation. Finally, functional changes in BBB permeabil-
ity might have a significant influence on the clinical effi-
cacy and tolerability of medication, which has to be inves-
tigated in larger trials.
 Limitations 
 Our data are limited by the relatively low number of 
patients per group and the lack of evaluation of other pos-
sible relevant factors for sICAM levels such as adiposity, 
diabetes, dyslipidemia, smoking behavior, hypertension 
or leptin levels. The inclusion criterion of a period of 4 
weeks in a stable state for euthymic patients might be too 
short. We further cannot conclude from our data that the 
increase in sICAM-1 levels is specific for patients with 
mood disorders. Differences in sICAM-1 levels between 
patients and controls may also be related to pharmaco-
logical treatment. However, a direct influence of different 
antidepressants on sICAM-1 levels was not detected, nei-
ther in a recent mouse model  [14] nor in a clinical trial 
 [13] . Finally, a direct correlation of sICAM-1 concentra-
tions and BBB dysfunction has so far not been shown.
 Taken together, our data offer the first evidence for a 
basal elevation of sICAM-1 in patients with unipolar and 
bipolar affective disorders, indicating chronic subclinical 
activation of the immune system and endothelial activa-
tion and dysfunction in the BBB.
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